Zhen-Xing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhen-Xing Wang has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Hui Xie
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China
28 shared publications Hao Yin
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China
11 shared publicationsYi-Wei Liu
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China
10 shared publicationsJiang-Shan Gong
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China
8 shared publications- Chun-Yuan Chen
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China
7 shared publications Guo-Qiang Zhu
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China
7 shared publications
Latest Publications
- RetractionOpen Access
- 27 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9152
Retraction Note: Aged bone matrix-derived extracellular vesicles as a messenger for calcification paradox
- 27 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9152
RetractionOpen AccessRetraction Note: Aged bone matrix-derived extracellular vesicles as a messenger for calcification paradox
- Open Access
- 27 July 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Magnetic field-controlled nanozymes effectively overcome therapeutic limitations in tumor ferroptosis therapy
Iron oxide nanozymes with intrinsic peroxidase-like activity and excellent biosafety are considered ideal agents for inducing tumor ferroptosis. However, t
- 27 July 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessMagnetic field-controlled nanozymes effectively overcome therapeutic limitations in tumor ferroptosis therapy
Iron oxide nanozymes with intrinsic peroxidase-like activity and excellent biosafety are considered ideal agents for inducing tumor ferroptosis. However, t
- Open Access
- 5 June 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 59, 101139
Pathological mechanisms of osteoarthritis in the network of geriatric comorbidities: Emerging insights from organs-crosstalk
- 5 June 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 59, 101139
Open AccessPathological mechanisms of osteoarthritis in the network of geriatric comorbidities: Emerging insights from organs-crosstalk
- Open Access
- 28 May 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Epigenetic brain reprogramming rejuvenates neuro-immune circuits to reverse Alzheimer’s disease pathology and systemic bone loss
Alzheimer's disease (AD) is characterized by progressive neurodegeneration, neuroinflammation, and systemic comorbidities, yet disease-modifying therapies remain elusive. Here, we show that partial epigenetic reprogramming via brain-restricted expression of Oct4, Sox2, and Klf4 (OSK) restores neuronal and neuroimmune homeostasis without loss of cellular identity. In APP/PS1 mice, OSK reprogramming improves cognitive performance across disease stages, reduces amyloid-β deposition, attenuates microglial activation, preserves synaptic integrity, and limits neuronal apoptosis. Mechanistically, reduced representation bisulfite sequencing reveals widespread reversal of AD-associated DNA methylation patterns, which is dependent on Tet2-mediated demethylation, establishing epigenetic rejuvenation as a key driver of functional recovery. Unexpectedly, brain-restricted OSK reprogramming also ameliorates systemic bone loss by reshaping brain-derived extracellular vesicle signaling, including modulation of miR-483-5p, thereby restoring osteogenic capacity. Together, these findings identify partial epigenetic reprogramming as a strategy to rewire neuro-immune circuits and link central nervous system rejuvenation to peripheral tissue homeostasis, providing a conceptual framework for targeting both neurodegeneration and its systemic consequences in AD.
- 28 May 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessEpigenetic brain reprogramming rejuvenates neuro-immune circuits to reverse Alzheimer’s disease pathology and systemic bone loss
Alzheimer's disease (AD) is characterized by progressive neurodegeneration, neuroinflammation, and systemic comorbidities, yet disease-modifying therapies remain elusive. Here, we show that partial epigenetic reprogramming via brain-restricted expression of Oct4, Sox2, and Klf4 (OSK) restores neuronal and neuroimmune homeostasis without loss of cellular identity. In APP/PS1 mice, OSK reprogramming improves cognitive performance across disease stages, reduces amyloid-β deposition, attenuates microglial activation, preserves synaptic integrity, and limits neuronal apoptosis. Mechanistically, reduced representation bisulfite sequencing reveals widespread reversal of AD-associated DNA methylation patterns, which is dependent on Tet2-mediated demethylation, establishing epigenetic rejuvenation as a key driver of functional recovery. Unexpectedly, brain-restricted OSK reprogramming also ameliorates systemic bone loss by reshaping brain-derived extracellular vesicle signaling, including modulation of miR-483-5p, thereby restoring osteogenic capacity. Together, these findings identify partial epigenetic reprogramming as a strategy to rewire neuro-immune circuits and link central nervous system rejuvenation to peripheral tissue homeostasis, providing a conceptual framework for targeting both neurodegeneration and its systemic consequences in AD.
- Open Access
- 22 May 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Organoids: generation strategies, applications, and future challenges
Organoids are microscopic 3D structures that resemble real organs, assembled in vitro from stem cells. Since the Dutch team of Hans Clevers successfully cu
- 22 May 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessOrganoids: generation strategies, applications, and future challenges
Organoids are microscopic 3D structures that resemble real organs, assembled in vitro from stem cells. Since the Dutch team of Hans Clevers successfully cu
- Top Cited PapersOpen Access
- 20 May 2026
- Published by Springer Nature in Bone Research
- Vol. 14 (1)
Akkermansia muciniphila attenuates intervertebral disc degeneration via extracellular vesicle-mediated delivery of the effector protein B2UKX5
Low back pain is a leading cause of global disability, with intervertebral disc degeneration (IVDD) as a primary contributor. Emerging evidence suggests a link between gut microbiota and disc health, yet the underlying mechanisms remain unclear. Through Mendelian randomization and a clinical cohort analysis, we identified a causal inverse relationship between Akkermansia muciniphila ( Akk ) abundance and IVDD risk, with reduced fecal Akk levels correlating with increased IVDD severity. Akk protected against IVDD in microbiota-depleted mice, and this protection was abolished by pharmacologic inhibition of extracellular vesicle (EV) secretion. Consistently, Akk -derived EVs ( Akk -EVs) recapitulated the benefits of Akk across natural aging, tail needle puncture, and bipedal standing mouse models, while control bacterium ( Escherichia coli ) and its EVs did not. Proteomics and functional validation identified B2UKX5 as a key Akk -EV-enriched effector protein. Furthermore, recombinant B2UKX5 attenuated IVDD in vivo and regulated critical pathways for disc homeostasis, including collagen synthesis, extracellular matrix remodeling, and chromatin silencing, as revealed by transcriptomic profiling of microdissected nucleus pulposus and annulus fibrosus tissues. Analysis of clinical samples further confirmed that Akk -EVs and B2UKX5 levels in circulation and intervertebral disc tissues were negatively correlated with IVDD severity. These findings establish a novel gut-disc axis, highlighting Akk , Akk -EVs, and B2UKX5 as promising therapeutic candidates for IVDD prevention and treatment.
- 20 May 2026
- Published by Springer Nature in Bone Research
- Vol. 14 (1)
Top Cited PapersOpen AccessAkkermansia muciniphila attenuates intervertebral disc degeneration via extracellular vesicle-mediated delivery of the effector protein B2UKX5
Low back pain is a leading cause of global disability, with intervertebral disc degeneration (IVDD) as a primary contributor. Emerging evidence suggests a link between gut microbiota and disc health, yet the underlying mechanisms remain unclear. Through Mendelian randomization and a clinical cohort analysis, we identified a causal inverse relationship between Akkermansia muciniphila ( Akk ) abundance and IVDD risk, with reduced fecal Akk levels correlating with increased IVDD severity. Akk protected against IVDD in microbiota-depleted mice, and this protection was abolished by pharmacologic inhibition of extracellular vesicle (EV) secretion. Consistently, Akk -derived EVs ( Akk -EVs) recapitulated the benefits of Akk across natural aging, tail needle puncture, and bipedal standing mouse models, while control bacterium ( Escherichia coli ) and its EVs did not. Proteomics and functional validation identified B2UKX5 as a key Akk -EV-enriched effector protein. Furthermore, recombinant B2UKX5 attenuated IVDD in vivo and regulated critical pathways for disc homeostasis, including collagen synthesis, extracellular matrix remodeling, and chromatin silencing, as revealed by transcriptomic profiling of microdissected nucleus pulposus and annulus fibrosus tissues. Analysis of clinical samples further confirmed that Akk -EVs and B2UKX5 levels in circulation and intervertebral disc tissues were negatively correlated with IVDD severity. These findings establish a novel gut-disc axis, highlighting Akk , Akk -EVs, and B2UKX5 as promising therapeutic candidates for IVDD prevention and treatment.
- 25 March 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 177, 116531
Dietary N-acetylneuraminic acid maintains intestinal homeostasis and protects against aging- and inflammation-associated colonic dysfunction
- 25 March 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 177, 116531
Dietary N-acetylneuraminic acid maintains intestinal homeostasis and protects against aging- and inflammation-associated colonic dysfunction
- Open Access
- 5 March 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (3) , 782-797
Local delivery of OSK factors enables partial cellular reprogramming to mitigate osteoarthritis and cartilage fibrosis
Osteoarthritis (OA) is a prevalent joint disease with a complex etiology, involving epigenetic alterations. Recent studies have suggested the potential of Oct4, Sox2 and Klf4 (OSK) in rejuvenating adult cells and facilitating tissue repair, but their specific role in OA pathophysiology and treatment remains unclear. Here we employed an adeno-associated virus (AAV) vector to achieve ectopic expression of OSK (AAV-OSK). Chondrocytes expressing OSK retained chondrocyte-specific markers with no increase in stemness-associated genes. AAV-OSK significantly preserved chondrocyte vitality in an inflammatory environment and counteracted the upregulation of osteogenic genes during OG differentiation. In OA murine models, AAV-OSK administration led to a notable improvement in cartilage integrity, a reduction in subchondral bone thickening and promoted the hyalinization of fibrocartilage. Furthermore, chondrocyte senescence and DNA methyltransferase expression were markedly diminished in the AAV-OSK group. Tet methylcytosine dioxygenase 2 was identified as a pivotal factor underlying the benefits of OSK-driven cartilage regeneration. Collectively, our study underscores that OSK expression within the knee joint modulates epigenetic alterations, mitigating OA progression and cartilage fibrosis through partial reprogramming, highlighting its therapeutic promise for comprehensive OA intervention.
- 5 March 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (3) , 782-797
Open AccessLocal delivery of OSK factors enables partial cellular reprogramming to mitigate osteoarthritis and cartilage fibrosis
Osteoarthritis (OA) is a prevalent joint disease with a complex etiology, involving epigenetic alterations. Recent studies have suggested the potential of Oct4, Sox2 and Klf4 (OSK) in rejuvenating adult cells and facilitating tissue repair, but their specific role in OA pathophysiology and treatment remains unclear. Here we employed an adeno-associated virus (AAV) vector to achieve ectopic expression of OSK (AAV-OSK). Chondrocytes expressing OSK retained chondrocyte-specific markers with no increase in stemness-associated genes. AAV-OSK significantly preserved chondrocyte vitality in an inflammatory environment and counteracted the upregulation of osteogenic genes during OG differentiation. In OA murine models, AAV-OSK administration led to a notable improvement in cartilage integrity, a reduction in subchondral bone thickening and promoted the hyalinization of fibrocartilage. Furthermore, chondrocyte senescence and DNA methyltransferase expression were markedly diminished in the AAV-OSK group. Tet methylcytosine dioxygenase 2 was identified as a pivotal factor underlying the benefits of OSK-driven cartilage regeneration. Collectively, our study underscores that OSK expression within the knee joint modulates epigenetic alterations, mitigating OA progression and cartilage fibrosis through partial reprogramming, highlighting its therapeutic promise for comprehensive OA intervention.
- 5 January 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (2) , 329-348
Brain neuron-derived WDFY1 induces bone loss
Brain health is closely linked to bone homeostasis. Skeletal aging is characterized by inadequate bone formation and marrow adiposity, but whether the brain contributes to this imbalance remains unknown. This study shows that aged brain neurons, mainly those in the hippocampus and cerebral cortex, produce excess WD repeat and FYVE domain containing 1 (WDFY1) protein and transfer it to the bone via extracellular vesicles (EVs), leading to bone-fat imbalance and osteoporosis. Increasing brain Wdfy1 expression causes premature skeletal aging. Conversely, suppressing Wdfy1 in the whole brain, hippocampus or neurons, genetically deleting neuronal Wdfy1, and selectively inhibiting neuronal EV release all improve bone health. Mechanistically, WDFY1 binds to the retromer complex to promote the endosome-to-Golgi recycling of cathepsin D and peroxiredoxin 2, thus inhibiting osteogenesis and augmenting adipogenesis. This study identifies the role of aged brain neuronal EVs as an important messenger in triggering bone-fat imbalance by transferring WDFY1 to bone.
- 5 January 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (2) , 329-348
Brain neuron-derived WDFY1 induces bone loss
Brain health is closely linked to bone homeostasis. Skeletal aging is characterized by inadequate bone formation and marrow adiposity, but whether the brain contributes to this imbalance remains unknown. This study shows that aged brain neurons, mainly those in the hippocampus and cerebral cortex, produce excess WD repeat and FYVE domain containing 1 (WDFY1) protein and transfer it to the bone via extracellular vesicles (EVs), leading to bone-fat imbalance and osteoporosis. Increasing brain Wdfy1 expression causes premature skeletal aging. Conversely, suppressing Wdfy1 in the whole brain, hippocampus or neurons, genetically deleting neuronal Wdfy1, and selectively inhibiting neuronal EV release all improve bone health. Mechanistically, WDFY1 binds to the retromer complex to promote the endosome-to-Golgi recycling of cathepsin D and peroxiredoxin 2, thus inhibiting osteogenesis and augmenting adipogenesis. This study identifies the role of aged brain neuronal EVs as an important messenger in triggering bone-fat imbalance by transferring WDFY1 to bone.
- Open Access
- 24 November 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2576658
Exploring the role of intelectin-1 in modulating asthma through the gut–bone–lung axis
The development of extra-intestinal diseases is often accompanied by disruptions in intestinal microbiota and its metabolites, yet the mechanistic link between the gut microbiota and asthma remains unclear. We investigated whether intelectin-1 (ITLN1) mitigates allergic asthma through the gut‒bone‒lung axis as a regulator of gut microbial homeostasis. Serum samples from 53 asthmatic patients and 34 healthy subjects were analyzed to assess the association between asthma and ITLN1 levels. Mechanism studies were conducted using a house dust mite (HDM)-induced asthma model in Itln1-knockout and Itln1-overexpression mice. Fecal samples were subjected to 16S rRNA sequencing, while lung tissues were analyzed using metabolomics and mRNA sequencing. Butyrate and CCL8-neutralizing antibody were used in the intervention studies, and human serum CCL8 levels were evaluated for clinical relevance. Serum ITLN1 levels inversely correlated with blood eosinophils in asthmatic patients. Itln1 deficiency exacerbated HDM-induced allergic lung inflammation, particularly type 2 inflammation, while Itln1 overexpression attenuated these effects. Fecal 16S rRNA analysis revealed reduced levels of Bifidobacteriaceae, Erysipelotrichaceae, and Muribaculaceae in Itln1-deficient asthmatic mice, mainly due to the loss of agglutination effects of ITLN1. Moreover, Itln1 deficiency correlated with decreased lung butyrate levels, further enhanced macrophage-derived CCL8 production using the NF-κB pathway and then activated CCR3 expression in CD4+ T cells from bone marrow. Noteworthily, butyrate supplementation or CCL8 neutralization effectively attenuated type 2 inflammation, especially in Itln1 deficiency condition. Additionally, human serum CCL8 levels exhibited a negative correlation with FEV1/FVC, FEV1, and FVC and a positive correlation with neutrophils under asthmatic conditions. ITLN1 is a promising therapeutic target linking gut microbial metabolism to asthma immune regulation using the gut‒bone‒lung axis.
- 24 November 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2576658
Open AccessExploring the role of intelectin-1 in modulating asthma through the gut–bone–lung axis
The development of extra-intestinal diseases is often accompanied by disruptions in intestinal microbiota and its metabolites, yet the mechanistic link between the gut microbiota and asthma remains unclear. We investigated whether intelectin-1 (ITLN1) mitigates allergic asthma through the gut‒bone‒lung axis as a regulator of gut microbial homeostasis. Serum samples from 53 asthmatic patients and 34 healthy subjects were analyzed to assess the association between asthma and ITLN1 levels. Mechanism studies were conducted using a house dust mite (HDM)-induced asthma model in Itln1-knockout and Itln1-overexpression mice. Fecal samples were subjected to 16S rRNA sequencing, while lung tissues were analyzed using metabolomics and mRNA sequencing. Butyrate and CCL8-neutralizing antibody were used in the intervention studies, and human serum CCL8 levels were evaluated for clinical relevance. Serum ITLN1 levels inversely correlated with blood eosinophils in asthmatic patients. Itln1 deficiency exacerbated HDM-induced allergic lung inflammation, particularly type 2 inflammation, while Itln1 overexpression attenuated these effects. Fecal 16S rRNA analysis revealed reduced levels of Bifidobacteriaceae, Erysipelotrichaceae, and Muribaculaceae in Itln1-deficient asthmatic mice, mainly due to the loss of agglutination effects of ITLN1. Moreover, Itln1 deficiency correlated with decreased lung butyrate levels, further enhanced macrophage-derived CCL8 production using the NF-κB pathway and then activated CCR3 expression in CD4+ T cells from bone marrow. Noteworthily, butyrate supplementation or CCL8 neutralization effectively attenuated type 2 inflammation, especially in Itln1 deficiency condition. Additionally, human serum CCL8 levels exhibited a negative correlation with FEV1/FVC, FEV1, and FVC and a positive correlation with neutrophils under asthmatic conditions. ITLN1 is a promising therapeutic target linking gut microbial metabolism to asthma immune regulation using the gut‒bone‒lung axis.